Life Sciences 2026

2026 Clinical Operations Hiring Report

By Darren Nelson, Founder & CEO, Recruits Lab

Quick Answer

Clinical Operations hiring grew 31 percent year-over-year in 2025, with the tightest demand at Director and VP level with pivotal-trial experience. Average Director Clinical Ops time-to-fill is 10-14 weeks. Compensation ranges from $210K-$440K base plus bonus and equity at venture-backed biotech.

Market data is directional and reflects Recruits Lab's proprietary 2024-2026 placement dataset combined with public benchmarks. Figures may vary by geography, company stage, industry, equity structure, bonus structure, and candidate experience. This report is an educational resource, not a definitive market survey.

Executive Summary

Clinical Operations is the single fastest-growing functional area in our 2025-2026 biotech dataset. Demand concentrated in Director and VP roles as venture-backed clinical-stage biotech advanced multiple programs into Phase 2 and Phase 3.

Pivotal-trial experience is the most-requested differentiator across our 2026 searches. Candidates with successful Phase 3 closeout in the last 5 years receive multiple active offers at decision time.

CRO oversight expertise has become table stakes. Director-level candidates are now expected to have negotiated and managed Tier 1 CRO master service agreements.

Hybrid and primary remote work remained dominant. Roughly 75 percent of our 2025 Director Clinical Ops placements allowed primary remote with quarterly site travel.

VP Clinical Operations searches grew through 2025 as multi-program companies consolidated clinical operations leadership under a single executive.

Hiring Demand

Clinical-stage biotech with Phase 2/3 programs drove demand. Cell/gene therapy and oncology were the tightest therapeutic areas.

→Director Clinical Operations: 31 percent year-over-year growth.
→Senior Director Clinical Operations: 26 percent growth.
→VP Clinical Operations: 19 percent growth.
→Clinical Trial Manager (Sr): 22 percent growth.
→Cell/gene therapy Clinical Ops: 38 percent growth from a small base.

Salary Trends

Base salaries rose 6-10 percent year-over-year for Director Clinical Ops and above. Pivotal-trial premiums widened. Equity refresh grants at 24 months became near-universal at the Director level.

Level	Range	Notes
Sr Clinical Trial Manager	$160K-$215K base + bonus + equity	—
Associate Director Clinical Ops	$190K-$260K base + bonus + equity	—
Director Clinical Operations	$210K-$310K base + bonus + equity	—
Senior Director Clinical Ops	$280K-$370K base + bonus + equity	—
VP Clinical Operations	$340K-$440K base + bonus + equity	—

Candidate Availability

Very Tight

Pivotal-trial credentialed Director and VP Clinical Ops talent is the scarcest population in our 2026 dataset. CRO oversight expertise at the Director level is moderately available; cell/gene therapy program leadership is very tight.

Pivotal-trial Director Clinical Ops: ~4 percent of available supply
Cell/gene therapy Clinical Ops leaders: scarce — fewer than 400 U.S.-wide
Counter-offer rate at Director+: ~60 percent
Average finalist evaluating 2-3 active offers

Time-to-Fill Benchmarks

Role	Typical Time-to-Fill	Notes
Sr Clinical Trial Manager	6-10 weeks	—
Associate Director Clinical Ops	8-12 weeks	—
Director Clinical Operations	10-14 weeks	—
Senior Director Clinical Ops	12-16 weeks	—
VP Clinical Operations	14-20 weeks	—

Geographic Hotspots

Market	Commentary
Boston / Cambridge	Deepest pivotal-trial credentialed pool.
San Francisco Bay Area	Strong cell/gene Clinical Ops density.
Greater Philadelphia / NJ	Cell and gene therapy hub.
Research Triangle (NC)	CRO alumni pool.
Remote (US)	~75 percent of Director-level roles allow primary remote.

Recruiting Challenges

Pivotal-trial Director-level supply is structurally constrained by the small number of programs reaching Phase 3 each year.
Counter-offer activity rose materially in 2025 as biotechs protected ongoing pivotal program execution.
Cell/gene therapy Clinical Ops leaders are concentrated in a handful of established programs and rarely move.
Roles requiring hybrid attendance at HQ close 30 percent slower than primary-remote equivalents.

Recruits Lab Insights

Director Clinical Ops placements with both pivotal-trial and CRO oversight evidence close 1.7x faster than single-attribute candidates.
Searches that articulate a 24-month clinical roadmap during first interviews close 1.4x faster.
VP Clinical Ops candidates evaluate the CEO and CMO as much as the asset; founder availability decides finalists.
Cell/gene therapy Clinical Ops mandates that flex on therapeutic area within cell/gene close 1.5x faster than single-indication searches.